



Murraya Koenigii Extract Attenuates Gene Expression of Endothelin-1 and VEGFR-2 and Upregulates NF-KB Genes in NRK-52 Cells Exposed to Glucotoxicity

Dr. Devaprasad Markandeyan¹, Dr. Palani Perumal², Dr. Shiek S.S.J. Ahmed³, Dr. Priyadarshini Shanmugam⁴, G. Bhavatharini⁵ Mohankumar A^{6*},

¹Professor, Head of the Neurology Department, Chettinad Academy of Research and Education, Tamilnadu, India.

²Professor, Director, and Head in the Department of Centre for Advanced Study in Botany, University of Madras.

³Drug Discovery Lab, Faculty of Allied Health Science, Chettinad Academy of Research and Education, Tamilnadu, India.

⁴Professor & Head, Department of Microbiology, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, Tamil Nadu-603103, India.

⁵Centre for Advanced Studies in Botany, University of Madras, Guindy Campus, Chennai.

⁶Corresponding author: Research scholar, Microbiology department, Chettinad Academy of Research and Education, Tamilnadu, India.

(Received: 04 February 2024

Revised: 11 March 2024

Accepted: 08 April 2024)

KEYWORDS

Murraya koenigii,
Endothelin-1,
VEGFR-2, HIF-
1 α genes

ABSTRACT:

Introduction: The Murraya koenigii plant, a member of the Rutaceae family, is renowned for its immunomodulatory and nephroprotective effects. Its leaves contain carbazole compounds known for their revitalizing properties, making Murraya koenigii a significant medicinal plant often utilized in Indian cuisine.

Aim: This study aimed to examine the influence of Murraya koenigii extract on gene expression in NRK-52E cells exposed to glucotoxic conditions.

Materials and methods: Fresh Murraya koenigii plants from Arakkonam, Ranipet District were harvested, washed, and dried. The dried plants were powdered and stored airtight. From this, 50 grams were methanol-extracted via Soxhlet for 4 days, yielding 12 grams of crude extract. A working solution was prepared by dissolving the crude extract powder (20mg) in DMSO (1 ml) for cell line treatment.

Results: The exposure to the extract significantly affected gene expression levels. Specifically, it attenuated the expression of Endothelin-1 and VEGFR-2 genes associated with certain physiological processes. Conversely, the extract led to upregulating HIF-1 α , TNF- α , and NF- κ B genes, indicating potential modulation of cellular responses and signaling pathways.

Conclusion: Murraya koenigii extract may offer renoprotective benefits against glucotoxicity-induced cellular damage by acting on Endothelin-1, VEGFR-2, and HIF-1 α genes, while its immunomodulatory activity may involve upregulation of TNF- α and NF- κ B genes.

1. Introduction

Murraya koenigii, an esteemed member of the Rutaceae family, holds a paramount position in traditional medicine. Renowned for its multifaceted benefits, the leaves of Murraya koenigii are rich in carbazole

compounds, known for their revitalizing properties and integral role in Indian culinary practices. Alongside carbazoles, these leaves harbor a diverse array of compounds such as terpenoids, flavonoids, and phenolics, each contributing to its medicinal prowess. These bioactive constituents have been extensively



studied and have shown promising therapeutic effects, including antioxidative, immunomodulatory, neuroprotective, hepatoprotective, antidiabetic, antitumor, and anti-inflammatory activities. Notably, in various animal models, *Murraya koenigii* extracts have exhibited nephroprotective properties, further underscoring its potential as a valuable botanical resource for holistic health and well-being.¹⁻⁷ Furthermore, *Murraya* leaves are employed in the management of diarrhea and dysentery, attributed to their potent antifungal and antimicrobial properties.⁸⁻¹⁰ *Murraya koenigii* juice is used to manage renal pains.¹¹ *koenigii* paste with milk is used to cure curing poisonous bites.¹²

2. Aim

This study aims to investigate the gene expression patterns of NRK-52 cells in cell culture exposed to high glucose levels and various concentrations of *Murraya koenigii* extract.

3. Methods

Murraya koenigii extract preparation

Fresh and healthy *Murraya koenigii* plants were harvested from an agricultural field in Arakkonam, Ranipet District. After washing, 500 grams of fresh plants were shade-dried for 3 days at room temperature. The dried sample was powdered using a Venus blender (India) and stored in a sterile, airtight container. Fifty grams of the powdered sample were then extracted with methanol (99%) using a Soxhlet apparatus for 4 days. The resulting extract was concentrated to dryness using a rotary evaporator, yielding 12 grams of crude extract. A working solution was prepared by dissolving the crude extract powder (20mg) in DMSO (1ml), which was then used to treat the cell lines with varying concentrations of the plant sample.

Cell culture

Table 1 Cell Culture Protocol	
Cells cultured	NRK-52E
Culture medium	DMEM
Supplements	Fetal bovine serum 10% (FBS, heat-inactivated), Penicillin 100 µg/mL,

	100 µg/mL amphotericin, Streptomycin 100 µg/mL, Sodium bicarbonate 3.7 g/L
Environment	37°C in an environment with 5% CO ₂
Cells Harvested	Confluence reached - 85 to 90% Cells seeded after Trypsin treatment- 1x 10 ⁶ Cell treatment time with plant extract- 24 hours

Table 2- Groups Analysed	
1.	1.Low glucose 5.5mM (1g/L)
2.	2.High glucose 30Mm (4.5g/L)
3.	3.High glucose 30Mm(4.5g/L) + 50µg/ml extract
4.	4.High glucose 30Mm(4.5g/L) + 100µg/ml extract
5.	5.High glucose 30Mm(4.5g/L) + 200µg/ml extract
6.	6.High glucose 30Mm (4.5g/L)+ 300µg/ml extract
7.	7.High glucose 30 Mm (4.5g/L) +400 µg/ml extract

MTT assay

The cell viability was assessed using the MTT assay from Sigma Aldrich. NRK-52 cells were cultured with different concentrations of *Murraya* extract in 96-well plates and incubated for 24 hours \ at 37°C in a 5% CO₂ environment. Following a 4-hour incubation in darkness at 37°C and DMSO treatment, absorbance was measured at 570 nm to determine % cell viability, according to the protocol.¹²

RNA Isolation and c- DNA library construction

RNA isolation was done using TRIZOL reagent by standard lab protocol involving precipitation by isopropanol and centrifugation at 12,000rpm at 4°C for 20 minutes.¹³ RNA quantification was done by nanodrop.

Real-time PCR analysis


The real-time qPCR was conducted for SIRT1, HIF-1 α , ET-1, and VEGFR-2 using SYBR green qPCR Mastermix (Takyon, Eurogentec). (Forward: F and Reverse: R) details are shown in Table 3.

**Table 3- Primer sequences**


Gene	Primer	Sequence
TNF-α	F	5'-CTTCTCCTTCCTGATCGTGG-3'
	R	5'-GCTGGTTATCTCTCAGCTCCA-3'
TGF-β	F	5'-TCGCCAGAGTGGTTATCTT-3'
	R	5'-TAGTGAACCCGTTGATGTCC-3'
NF-κB	F	5'-CCATGACAGCAAATCTCC-3'
	R	5'-TAAACTTCATCTCCACCCC-3'
HIF-1α	F	5'GCCGCTGGAGACACAATCAT3'
	R	5'GAAGTGGCTTTGGCGTTTCA3'
ET-1	F	5'CAGGGCTGAAGACATTATGGA3'
	R	5'CATGGTCTCCGACCTGGTTT3'
VEGFR-2	F	5'CGGACAGTGGTATGGTTCTTGC3'
	R	5'GTGGTGTCTGTGTCATCGGAGTG3'

The following thermal cycler program were performed for PCR amplification. 3 minutes at 95 °C for initial denaturation, denaturation at 95°C for 10 seconds, and 60°C for primer annealing, the cycle threshold (CT) values obtained were analyzed by the 2 – $\Delta\Delta$ CT formula.


4. Results

**Fig 1:** Viability of NRK-52 Cells MTT Assay.

Normal glucose (NG) treated cells, High glucose (HG) treated cells, HG+50,100,200,300,400- High glucose exposed cells treated with 50,100,200,300,400 μ g concentration *Murraya koenigii* extract treatment for the Viability of NRK-52 Cells which showed in Figure 1.

**Fig 2:** Relative gene expression of TGF- β gene

NG, HG, HG+50,100,200,300,400- High glucose exposed cells treated with 50,100,200,300,400 μ g concentration *Murraya koenigii* extract treatment for the gene expression of β gene were shown in Figure 2.

**Fig 3:** Relative gene expression of NF- κ B gene

NG, HG, HG+50,100,200,300,400- High glucose exposed cells treated with 50,100,200,300,400 μ g concentration *Murraya koenigii* extract treatment for NF- κ B gene expression shown in Figure 3.




Fig 4: Relative gene expression of TNF-α gene

NG, HG, HG+50,100,200,300,400- High glucose exposed cells treated with 50,100,200,300,400 µg concentration *Murraya koenigii* extract treatment for the TNF-α gene were shown in Figure 4.




Fig 5: Relative gene expression of ET-1 gene

NG, HG, HG+50,100,200,300,400- High glucose exposed cells treated with 50,100,200,300,400 µg concentration *Murraya koenigii* extract treatment for ET-1 gene expression shown in Figure 5.




Fig 6: Relative gene expression of VEGFR-2 gene

NG, HG, HG+50,100,200,300,400- High glucose exposed cells treated with 50,100,200,300,400 µg concentration *Murraya koenigii* extract treatment for the expression of VEGFR-2 gene were shown in Figure 6.




Fig 7: Relative gene expression of HIF-1α gene

NG, HG, HG+50,100,200,300,400- High glucose exposed cells treated with 50,100,200,300,400 µg concentration *Murraya koenigii* extract treatment for the gene expression of HIF-1α shown in figure 7.

Exposure of renal tubular epithelial cells NRK-52 to high glucose (30 mM) and *Murraya* extracts of various concentrations did not significantly change cell viability. *Murraya* extract exposure increased the expression of TGF-β in cells predominantly in 50mcg, 200mcg, and 400mcg concentrations. *Murraya* extract exposure increased the expression of TNF-α in all concentrations in a dose-related manner. *Murraya* extract exposure increased expression of NFKB in all concentrations predominantly in 50mcg and 100mcg concentrations. *Murraya* extract caused a dose-related reduction in the expression of ET1 genes from the 50 to 200 mcg dose range and VEGFR2 expression from the 50 to 300 mcg dose range. These two genes were upregulated by high glucose exposure.

5. Discussion

Our study shows that *Murraya* extract stimulates the expression of important immune genes like NFKB, TNF-α, and TGF-β. *Murraya* extract also reduces the expression of ET-1 and VEGFR2. The immune-stimulating properties may be detrimental in the case of diabetic nephropathy. In a model involving immunity to ovalbumin, *Murraya* extract was shown to increase NO production and phagocytic activity and stimulate humoral immunity. (Shah.A.S 2008).¹³ Our studies show upregulate inTGF-β, NFKB, and TNF-α genes which



also confirms the immune stimulatory potential of *Murraya*.

Murraya has been shown to have a nephroprotective effect in rat diabetic nephropathy models and it was demonstrated to be due to antioxidant capacity and renal myeloperoxidase activity (Yankuzo. H 2011).¹⁴ *Murraya* extract helped to maintain high glutathione (GSH) and superoxide dismutase (SOD) levels in kidneys and reduced cyclophosphamide-induced nephrotoxicity (Mahipal 2017).¹⁵ *Murraya* was also found to decrease serum creatinine and help in maintaining normal renal histology and help tissue regeneration in kidneys (Purnuru 2014).¹⁶ Though all these activities were previously attributed to antioxidant properties, the decrease in ET-1 gene and VEGFR-2 gene expression following *Murraya* extract treatment in renal tubular cells may contribute to the nephroprotective activity of *Murraya koenigii*. There is enough literature regarding the usefulness of antagonizing ET-1, and VEGFR-2 in treating diabetic nephropathy. Plasma and urinary Endothelin-1 levels were elevated in patients with diabetic nephropathy and antagonizing ET1 receptors was shown to be beneficial to diabetic kidneys (Peppas-Patrikiou et al., 1998; Wenzel et al., 1999).^{17,18} A VEGFR2 pathway-activation blockade improved renal function and alleviated glomerular damage in diabetic mice models (Lavoze et al., 2020).¹⁹ The increase in HIF-1 α gene expression following *Murraya* extract treatment in renal tubular cells may also contribute to the nephroprotective activity. Yu. L *et al* have shown that HIF-1 α activated Parkin/PINK1-mediated mitophagy and this action prevented apoptosis and ROS production in HK-2 cells subjected to high glucose exposure thereby alleviating Diabetic nephropathy.²⁰

6. Conclusion:

Our study demonstrates that *Murraya koenigii* extract can modulate the gene expression pattern in NRK-52 cells under high glucose conditions, suggesting its potential immunomodulatory and nephroprotective effects.

References:

1. Ma, Q. G.; Xu, K.; Sang, Z. P.; Wei, R. R.; Liu, W. M.; Su, Y. L.; Yang, J. B.; Wang, A. G.; Ji, T. F.; Li, L. J. Alkenes with antioxidative activities from *Murraya koenigii* (L) Spreng. *Bioorg. Med. Chem. Lett.* 2016, 26, 799–803. [CrossRef]
2. Chatterjee, P.; Seal, S.; Mukherjee, S.; Kundu, R.; Bhuyan, M.; Barua, N. C.; Baruah, P. K.; Babu, S. P. S.; Bhattacharya, S. A carbazole alkaloid deactivates mTOR through the suppression of rictor and that induces apoptosis in lung cancer cells. *Mol. Cell. Biochem.* 2015, 405, 149–158. [CrossRef] [PubMed]
3. Das, R.; Bhattacharya, K.; Sarkar, S.; Samanta, S. K.; Pal, B. C.; Mandal, C. Mahanine synergistically enhances cytotoxicity of 5-fluorouracil through ROS-mediated activation of PTEN and p53/p73 in colon carcinoma. *Apoptosis* 2014, 19, 149–164. [CrossRef] [PubMed]
4. Agarwal, S.; Amin, K. S.; Jagadeesh, S.; Baishay, G.; Rao, P. G.; Barua, N. C.; Bhattacharya, S.; Banerjee, P. P. Mahanine restores RASSF1A expression by down-regulating DNMT1 and DNMT3B in prostate cancer cells. *Mol. Cancer* 2013, 12, 99. [CrossRef] [PubMed]
5. Mahipal, P.; Pawar, R. S. Nephroprotective effect of *Murraya koenigii* on cyclophosphamide-induced nephrotoxicity in rats. *Asian Pac. J. Trop. Med.* 2017, 10, 808–812. [CrossRef]
6. Rautela, R.; Das, G. K.; Khan, F. A.; Prasad, S.; Kumar, A.; Prasad, J. K.; Ghosh, S. K.; Dhanze, H.; Katiyar, R.; Srivastava, S. K. Antibacterial, anti-inflammatory and antioxidant effects of *Aegle marmelos* and *Murraya koenigii* in dairy cows with endometritis. *Livest. Sci.* 2018, 214, 142–148. [CrossRef]
7. Mani, V.; Ramasamy, K.; Ahmad, A.; Wahab, S. N.; Jaafar, S. M.; Kek, T. L.; Salleh, M. Z.; Majeed, A. B. A. Effects of the total alkaloidal extract of *Murraya koenigii* leaf on oxidative stress and cholinergic transmission in aged mice. *Phyther. Res.* 2013, 27, 46–53.
8. Nalli, Y.; Khajuria, V.; Gupta, S.; Arora, P.; Riyaz-Ul-Hassan, S.; Ahmed, Z.; Ali, A. Four new carbazole alkaloids from *Murraya koenigii* that display anti-inflammatory and anti-microbial activities. *Org. Biomol. Chem.* 2016, 14, 3322–3332. [CrossRef]
9. Joshi, T.; Jain, T.; Mahar, R.; Singh, S. K.; Srivastava, P.; Shukla, S. K.; Mishra, D. K.; Bhatta, R. S.; Banerjee, D.; Kanojjiya, S. Pyranocarbazoles



- from *Murraya koenigii* (L) Spreng. as antimicrobial agents. *Nat. Prod. Res.* 2018, 32, 430–434. [CrossRef]
10. Sharma, S.; Handu, S.; Dubey, A.; Sharma, P.; Mediratta, P.; Ahmed, Q. Anti-anxiety and antidepressant like effects of *Murraya koenigii* in experimental models of anxiety and depression. *Anc. Sci. Life* 2017, 36, 215–219.
11. Tembhurne, S.V.; Sakarkar, D.M. Hypoglycemic effects of fruit juice of *Murraya koenigii* (L) in alloxan induced diabetic mice. *Int. J. PharmTech Res.* **2009**, 1, 1589–1593.
12. Sim, K.M.; Teh, H.M. A new carbazole alkaloid from the leaves of Malayan *Murraya koenigii*. *J. Asian Nat. Prod. Res.* **2011**, 13, 972–975. [CrossRef] [PubMed]
13. Shah, A.S.; Wakade, A.S.; Juvekar, A.R. Immunomodulatory activity of methanolic extract of *Murraya koenigii* (L) Spreng. leaves. *Indian J. Exp. Biol.* **2008**, 46,
14. Yankuzo, H.; Ahmed, Q.U.; Santosa, R.I.; Akter, S.F.U.; Talib, N.A. Beneficial effect of the leaves of *Murraya koenigii* (Linn.) Spreng (Rutaceae) on diabetes-induced renal damage in vivo. *J. Ethnopharmacol.* **2011**, 135, 88–94
15. Mahipal, P.; Pawar, R.S. Nephroprotective effect of *Murraya koenigii* on cyclophosphamide induced nephrotoxicity in rats. *Asian Pac. J. Trop. Med.* **2017**, 10, 808–812. [CrossRef]
16. Punuru, P.; Sujatha, D.; Kumari, B.P.; Charisma, V.V.L. Evaluation of aqueous extract of *Murraya koenigii* in unilateral renal ischemia reperfusion injury in rats. *Indian J. Pharmacol.* **2014**, 46, 171–175.
17. Peppas-Patrikiou, M., Dracopoulou, M., & Dacou-Voutetakis, C. (1998). Urinary endothelin in adolescents and young adults with insulin-dependent diabetes mellitus: relation to urinary albumin, blood pressure, and other factors, *Metabolism*, 47, 1408–1412.
18. Wenzel, R.R., Czyborra, P., Luscher, T., & Philipp, T. (1999). Endothelin in cardiovascular control: the role of endothelin antagonists, *Curr. Hypertens Rep.*, 1, 79–87. <https://doi.org/10.1007/s11906-999-0077-7>
19. Lavozy, C., Rodriguez-Diez, R.R., Plaza, A., Carpio, D., Egido, J., Ruiz-Ortega, M., & Mezzano, S. (2020). VEGFR2 Blockade Improves Renal Damage in an Experimental Model of Type 2 Diabetic Nephropathy. *Journal of Clinical Medicine*, 9(2), 302.
20. Yu, L., Wang, Y., Guo, Y. H., Wang, L., Yang, Z., Zhai, Z. H., & Tang, L. (2022). HIF-1 α Alleviates High-Glucose-Induced Renal Tubular Cell Injury by Promoting Parkin/PINK1-Mediated Mitophagy. *Frontiers in medicine*, 8, 803874.